Biohaven begins enrolment in Phase III trial of rimegepant for migraine

Biohaven Pharmaceutical Holding has begun patient enrolment in the first of two Phase III clinical trials planned for its product candidate rimegepant (BHV-3000) for acute treatment of migraine.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news